source: Acer Therapeutics
EDSIVO (celiprolol) is being studied for the treatment of vascular Ehlers-Danlos Syndrome, or vEDS, in the United States. Celiprolol is a chemical entity originally developed to treat hypertension. Celiprolol is believed to provide clinical benefit for people with vEDS by promoting normal collagen synthesis in the blood vessels, and by shifting the pressure load away from the vessels most prone to dissection and rupture. Although it can also be used to treat mild to moderate hypertension (high blood pressure), celiprolol does not lower blood pressure in people with normal blood pressure.
In a study of people with vEDS in eight centers in France and one in Belgium, 53 people with vEDS were randomized to either a treatment group (25 people) or non-treated control group (28 people). Those in the treatment group received up to 400 mg of celiprolol per day (200 mg by mouth twice daily). Twenty percent of people in the celiprolol-treated group had an arterial event (either rupture or dissection) versus fifty percent of the non-treated control group. This demonstrates a significant reduction in risk for arterial events in the group being treated when compared to the non-treated control group. As well, very few adverse events or side effects of treatment were reported; two people reported fatigue and one person discontinued treatment due to extreme fatigue.